Eine Studie mit Nivolumab und Ipilimumab bei zuvor unbehandelten Patienten mit NSCLC im Stadium 3, das entweder inoperabel ist oder bei dem keine chirurgische Entfernung des Tumors geplant ist

Biological: nivolumab;Biological: ipilimumab;Biological: durvalumab

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status =1

- Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0)
pathologically-confirmed NSCLC, according to 8th TNM classification. Participants who
are not planned for potential curative surgical resection are eligible.

- Newly diagnosed and treatment-na?ve, with no prior local or systemic anticancer
therapy given as primary therapy for locally advanced disease

Exclusion Criteria:

- Any condition including medical, emotional, psychiatric, or logistical that, in the
opinion of the Investigator would preclude the participant from adhering to the
protocol or would increase the risk associated with study participation

- Active infection requiring systemic therapy within 14 days prior to randomization

- History of organ or tissue transplant that requires systemic use of immune suppressive
agents

- Prior thoracic radiotherapy

Other protocol-defined inclusion/exclusion criteria apply